For more study specific information or to refer patients, please contact our research coordinators directly.
Interventional Studies: Biological Studies for Early Parkinson's Disease
Sure - PD Inosine for Early PD (Enrolling)
This is a two and a half year long clinical trial to test Inosine's efficacy in slowing the progression of Parkinson's Disease (PD). This study seeks to evaluate what may show to be a neuroprotective agent for early PD patients who have not yet developed sufficient motor symptom disabilities that require treatment with anti- Parkinsonism therapies. Eligible patients are over 30 years of age who are currently NOT taking dopaminergic medications and have been diagnosed with Parkinson's Disease for less than three years. For further information about this study please contact our research coordinators at email@example.com. See brochure
Antibodies Against Alpha-Synuclein (active; with limit anti-Parkinson's treatment)
This clinical trial is an approximately 20 week long study to evaluate whether a single dose of an investigational immunotherapy (antibody) drug given intravenously is safe and well-tolerated in PD patients. The drug is designed to bind to and remove the alpha-synuclein, which is believed to build up to abnormally high levels in the brains of subjects with PD. This is a single dose study involving a pre-dose lumbar puncture followed by 6 day / 5 night inpatient stay with 24 hour continuous heart monitoring and two post infusion lumbar punctures. Additional study activities include 3 MRIs, 1 DaTScan, clinical evaluations, neuropsychological testing, and blood sample collections. Eligible patients are between 40 - 80 years of age who have been diagnosed with Parkinson's disease for less than five years, have no motor fluctuations or dyskinesias, are not receiving symptomatic PD treatment (no dopamine agonists/selegiline/rasagiline in last 3 months & no levadopa in last 30 days), and are willing ot remain off symptomatic PD medications during study. For further information about this study, please contact our research coordinator Tel: 858-2462537.
Neurodegenerative Disorders Cerebrospinal Fluid (CSF) Biorepository
The UCSD Movement Disorder Center is conducting a study to learn more about Parkinsonian diseases by collecting cerebrospinal fluid (CSF), the fluid that the brain sits in, samples for future research. Non-UCSD patients will first need to be seen at UCSD to confirm the disgnosis and meidcal history. Participation will include 1 study visit to complete a lumbar puncture.
Neurodegenerative Disorders Blood BIorepository
The UCSD Movement Disorder Center is conducting a study to learn more about Parkinsonian diseases by collecting blood samples for future research. Non-UCSD patients will first need to be seen at UCSD to confirm the disgnosis and meidcal history. Participation will include 1 study visit to complete a blood draw.
Interventional Studies: PD with Fluctuations
Dopamine Agonist for PD Patients with Fluctuations (Enrolling)
This Clinical trial is approximately 23 weeks/161 day long study comparing the effectiveness of a new D1/D5 Dopamine Agonist when taken with L-Dopa versus only taking L-Dopa alone for the management of "OFF" episodes. This new dopamine agonist may have the potential to reduce OFF time in subjects with PD who are experiencing significant OFF time despite their current dopaminergic therapy. Patients eligible for this study should have a meaningful response to L-Dopa with well- defined "OFF" time duration of >2.5 house during the waking day. Patients must be on at least 400mg/day of L- Dopa/day for 28 days prior to enrollment and should not have memory problems. For further information please contact our research coordinator email: firstname.lastname@example.org. See brochure
Efficacy of RO7046015 Drug in Patients with Early PD (Roche)
In collaboration with Roche, this study will evaluate the efficacy of RO7046015 versus placebo, in participants with early PD who are untreated or treated with monoamine oxidase-B (MAO-B) inhibitors since baseline, as measured by change from baseline over 52 weeks on the MDS-UPDRS Total Score,. Includes DaT-SPECT, CSF collection and following scales: CGI-I, PGIC, MDS-UPDRS subscales, H&Y, SE-ADL, MoCA,HADS, PAC-SYM, SCOPA-AUT, PDSS-2, PDQ-39, and smarphone and wrist-worn wearable assessments.
Closed to enrollment. Please contact email@example.com for more information.
Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with PD
In collaboration with Biogen, this study will evaluate the dose-related safety, PD & PK of BIIB054 in clinicically established PD patients diagnosed within a mezimum of 3 years. Subjects will be enrolled in 2 cohorts. Cohort A will be randomized first and when they complete their Week 12 assessments, Cohort B will be randomized. 6 Study Visits will be performed with optional MRIs/ PET scans and genetic testing.
Open to enrollement. To learn more about this study, contact firstname.lastname@example.org.
T-cell mediated autoimmune responses in PD (MJFF)
The research study's goal is to develop a biomarker of responsiveness to quantify alpha-synuclein (a-sin) responsive T cells in PD patients. Eligible participants would come in for one study visit to donate blood (250 mL).
Please contact email@example.com for more information.
PD Observational Studies
Cognition in PD and related Disorders
Dr. J. Vincent Filoteo’s group is conducting cross sectional and longitudinal studies of cognition (e.g., memory, attention, problem solving) in patients with Parkinson's disease (PD) and related disorders. Their goal is to better characterize the nature of neuropsychological and psychological changes in individuals with PD as well as identify novel predictors of future cognitive decline. Please contact Dr. Filoteo's research coordinator at 858-552-8585 ext 5593 if you are interested in participating, or if you would like to refer a patient to our study. Link to Dr. Filoteo's publications.
- Prospective Memory Deficits are Associated with Poorer Everyday Functioning in PD. See the pdf.
- Validation of the Modified Fatigue Impact Scale in Parkinson's Disease. See the pdf.
- Implicit Category Learning Performance Predicts Rate of Cognitive Decline in Nondemented Patients With Parkinson's Disease. See the pdf.
Educational Toolkit for Hispanic PD Community (MJFF)
To develop and perform qualitative interviews with Hispanic PD patients, their caregivers, and healthcare providers serving Hispanic predominant communities in order to identify their perceived barriers related to participating in PD research and their understanding of PD.
Contact Lisa Damron for more information at firstname.lastname@example.org.
Patient Outcomes Project and Patient Registry Study
The goal of this program is to have a cohort of 500 patients followed at each center, with 200 patient data forms to be submitted within the next twelve months. This observational study only involves PD patients, whose medical history, UPDRS, H&Y, and other data will be collected.
Contact Lisa Damron for more information at email@example.com.
Dr. Michael P. Caligiuri kinematic research studies of handwriting movements to identify writer-based sources of variability in signature authentication in movement disorders and dementia for forensic applications. Please contact Christina Gigliotti, PhD, at 858-246-1243 for more information about these exciting opportunities. Link to Dr. Caligiuri's publications.
Using MRI to study cognitive changes
Dr. Deborah Harrington’s lab uses functional and structural magnetic resonance imaging to study the neural bases for cognitive changes in Parkinson’s disease. The goal is to identify early signatures of dysfunction in brain networks that support cognition and to explore individual differences in the risk for cognitive decline. If you are interested in participating or would like to refer a potential volunteer, please contact Dr. Harrington’s research coordinator at 858-642-6392. Link to Dr. Harrington's publications.
Using technology to study sensorimotor deficits in PD
Dr. Howard Poizner’s lab is using contemporary technologies for 3D motion analysis, robotics, and immersive virtual reality, in conjunction with noninvasive brain imaging (EEG), to examine the nature of the sensorimotor deficits in Parkinson's disease and the effects of drug versus surgical therapies in ameliorating these deficits.
Our goal is to better understand the functional roles of basal ganglia-cortical circuits in motor control and sensorimotor learning, and, in the process, to provide quantitative, objective assessments of motor dysfunction and specific effects of therapies. Find out about participating in our studies at the Poizner Lab website.